In vitro and in vivo experiments demonstrated that TWF2 promotes RCC progression and sunitinib resistance by interacting with YAP at the specific residues TWF2 M99 and YAP M225, thereby inhibiting Hippo signaling and stabilizing YAP by preventing ubiquitination and degradation. Here, TWF2 is linked to renal cell carcinoma.